These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 26993495

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
    Oka S, Kai T, Hoshino K, Watanabe K, Nakamura J, Abe M, Watanabe A.
    BMC Cardiovasc Disord; 2021 Apr 29; 21(1):217. PubMed ID: 33926386
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease.
    Moriwaki K, Takeuchi T, Fujimoto N, Sawai T, Sato Y, Kumagai N, Masuda J, Nakamori S, Ishida M, Yamada N, Nakamura M, Sakuma H, Ito M, Dohi K.
    Circ J; 2018 Jul 25; 82(8):2119-2127. PubMed ID: 29760346
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov 02; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Dissipative energy loss within the left ventricle detected by vector flow mapping in diabetic patients with controlled and uncontrolled blood glucose levels.
    Li CM, Bai WJ, Liu YT, Tang H, Rao L.
    Int J Cardiovasc Imaging; 2017 Aug 02; 33(8):1151-1158. PubMed ID: 28299608
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK, Smith SM, Park H.
    Cardiovasc Diabetol; 2018 Jul 17; 17(1):102. PubMed ID: 30016946
    [Abstract] [Full Text] [Related]

  • 56. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
    Harmer JA, Keech AC, Veillard AS, Skilton MR, Marwick TH, Watts GF, Meredith IT, Celermajer DS, FIELD Vascular Study Investigators.
    Atherosclerosis; 2015 Sep 17; 242(1):295-302. PubMed ID: 26233916
    [Abstract] [Full Text] [Related]

  • 57. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
    Kostev K, Schokker E, Jacob L.
    Int J Clin Pharmacol Ther; 2018 Sep 17; 56(9):411-416. PubMed ID: 30049306
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition.
    Zhong J, Goud A, Rajagopalan S.
    Circ Heart Fail; 2015 Jul 17; 8(4):819-25. PubMed ID: 26199308
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.